No Data
Bocom Intl: Maintains 'buy' rating on Beigene (06160) with a target price of HKD 156.
Bocom Intl has raised the peak global sales forecast for Zejula from 4.4 billion to 5.2 billion.
[Brokerage Focus] BOCOM Intl raised Beigene (06160) target price by 23.8%, indicating that its new wave of innovative achievements is ready to be released.
According to the research report released by Bocom intl, Beigene (06160) achieved a adjusted non-GAAP operating profit of 0.048 billion US dollars (same below) in 2Q24, successfully turned losses into profits (2Q23: 0.193 billion). The bank raised the global sales peak forecast of zebutinib from 4.4 billion to 5.2 billion. The bank pointed out that a new wave of innovative achievements is waiting to be released: 1) Sonrotoclax (Bcl-2) first registration clinical study (global single-arm II phase treatment r/rMCL) has completed enrollment and is expected to complete follow-up, data cleaning and market application declaration in about a year, and the bank expects to
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Citigroup Maintains Buy on BeiGene, Raises Price Target to $288
BeiGene Analyst Ratings
Health Check: How Prudently Does BeiGene (NASDAQ:BGNE) Use Debt?
No Data
